This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amazon (AMZN) Plunges 19.1% in a Month: Should You Buy the Dip?
by Shilpa Mete
Amazon (AMZN) stock falls on a weak third-quarter 2024 guidance amid strength in the cloud computing business, which holds long-term promise.
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal
by Zacks Equity Research
Amazon's (AMZN) AWS partners with Exscientia to power the latter's platform for end-toend drug discovery and automation.
How Much Upside is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43%
by Zacks Equity Research
The mean of analysts' price targets for Exscientia (EXAI) points to a 61.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 57.2% in Exscientia (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Exscientia (EXAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Brian's Big Idea on Healthcare
by Brian Bolan
Big moving drug stocks and the HealthCare Innovators service at Zacks.
Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 68% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Dynavax Technologies (DVAX) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.
Wall Street Analysts Believe Exscientia PLC Sponsored ADR (EXAI) Could Rally 76.12%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 76.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is a Surprise Coming for Exscientia (EXAI) This Earnings Season?
by Zacks Equity Research
Exscientia (EXAI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.
Does Exscientia PLC Sponsored ADR (EXAI) Have the Potential to Rally 104.18% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 104.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for October 25th
by Zacks Equity Research
RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023.
Wall Street Analysts Predict a 99.07% Upside in Exscientia PLC Sponsored ADR (EXAI): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 99.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a Turnaround
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 12.50% and 11.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 62.6% in Exscientia PLC Sponsored ADR (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.